The MARK-B™ COVID-19 test delivers results in 10 minutes on our unique MARK-B™ analyzer; making it more accurate than conventional RDT products. POCT with increased sensitivity is essential for the reliable detection of SARS-CoV-2 and enables immediate, effective treatment decisions.
The MARK-B™ COVID-19 Antigen S is CE marked, the Ab test will be followed soon.
COVID-19 Antigen S Test
Limit of Detection:
TCID 2.4 x10 per mL
Qualitative detection of SARS-CoV-2 spike proteins
Sensitivity 98.5% , Specificity 98.5 %
Fast results within 10 mins
Specimen : nasopharyngeal swab
Fully automated analysis
Once inserted into the instrument, the sample is separated into plasma by our patent technology.
In succession, the electrochemical analysis process begins.
No need for pre-processing
Quick turnaround 10mins
by electrochemical method
MARK-B™ utilizes MESIA,
a patented technology of BBB inc.
Published Journal Paper
“MESIA: Magnetic force-assisted electrochemical sandwich immunoassays for quantification of prostate-specific antigen in human serum”
- <Analytica Chimica Acta>, March, 2019
_ PhD. Hyundoo Hwang, Leader of BBB R&D Center
High expandability in test portfolio
*Not available for sale
*Scheduled to release in 2020
Cloud server to communicate with MARK-B™ test results
POCT1-A2 protocol, HL7, FHIR® to communicate with DMS
Android based Analyzer software
**Depends on the analyte